| Literature DB >> 32605271 |
Anna Jakubczyk1, Monika Karaś1, Piotr Stanikowski2, Beata Rutkowska3, Magdalena Dziedzic3, Ewelina Zielińska4, Konrad A Szychowski5, Urszula E Binduga5, Kamila Rybczyńska-Tkaczyk6, Barbara Baraniak1.
Abstract
The aim of the study is to characterise biologically active hydolysates and peptide fractions obtained from vacuum-packed string beans (Phaseolus vulragis L.) (PB). Unpacked beans were a control sample. The influence on human squamous carcinoma cell line SCC-15 (ATCC CRL-1623) was determined. Packed bean (PB) and unpacked bean (UB) extracts were found to exert no effect on the tongue squamous carcinoma cells. The results of the study indicated that the packing process contributed to the retention of protein, soluble dietary fibre, and free sugar (2.36, 3.5, and 1.79 g/100 d.m., respectively). PB was characterised by higher antioxidant activity (expressed as neutralisation of 2,2'-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid (ABTS ABTS•+) and 2,2-diphenyl-1-picrylhydrazyl (DPPH·) free radicals) as well as Fe2+ chelation and reducing power (IC50 = 54.56, 0.46, 3.85 mg mL-1; 0.088 A700/peptide content, respectively) than the UB samples before hydrolysis. The hydrolysis process enhanced these properties. The IC50 value of lipase and α-amylase inhibitory activity of the hydrolysates obtained from UB was reduced. The PB and UB fractions exhibited a certain level of antimicrobial activity against S. aureus and E. coli. Candida albicans were not sensitive to these peptide fractions.Entities:
Keywords: bioactive peptides; in vitro digestion; nutritional potential; string bean; vacuum-packing
Year: 2020 PMID: 32605271 PMCID: PMC7404719 DOI: 10.3390/foods9070842
Source DB: PubMed Journal: Foods ISSN: 2304-8158
Figure 1Effect of increasing concentrations (0.0012, 0.0025, 0.0050, and 0.0100 mg) of extracts from the PB (packed string bean) and UB (unpacked string bean) on resazurin reduction in SCC-15 cells after 24 (A), 48 (B), and 72 h (C). The data are expressed as the means ± SEM of four independent experiments, each of which consisted of eight replicates per treatment group. The samples did not show statistically significant differences.
Content of selected compounds in packed (PB) and unpacked (UB) string beans.
| Select Compounds of String Bean (g/100 d.m.) | ||||
|---|---|---|---|---|
| Sample | Protein | Soluble Dietary | No Soluble Dietary Fibre | Free Sugars |
| PB | 2.36 ± 0.17 b | 3.5 ± 0.81 b | 1.14 ± 0.38 a | 1.79 ± 0.03 a |
| UB | 1.82 ± 0.13 a | 2.97 ± 0.98 a | 1.20 ± 0.40 a | 1.74 ± 0.03 a |
d.m.—dry mass; PB - packed sreing bean; UB—unpacked string bean.The data were analysed with one-way analysis of variance (ANOVA), followed by Tukey’s multiple comparison procedure. Different letters in the same column indicate significant differences (α = 0.05).
Figure 2Peptide content in each step of digestion. All values are the mean ± standard deviation for triplicate experiments. The data were analysed with one-way analysis of variance (ANOVA) followed by Tukey’s multiple comparison procedure. Different lowercase letters at the same enzyme indicate significant differences (α = 0.05).
Potential bioaccessibility (PAC) and bioavailability (PAV) factors of peptide fractions obtained from PB and UB.
| Factor | PB | UB | ||||
|---|---|---|---|---|---|---|
| PAC | 1.86 | 2.21 | ||||
| <3.5 kDa | 3.5–7.0 kDa | <7.0 kDa | <3.5 kDa | 3.5–7.0 kDa | <7.0 kDa | |
| PAV | 6.04 | 4.21 | 1.87 | 1.23 | 1.27 | 2.14 |
PB—packed sreing bean; UB—unpacked string bean.
Antioxidant activity of samples (IC50).
| Sample | ABTS | DPPH | Fe2+ Chelation | Reducing Power | ||||
|---|---|---|---|---|---|---|---|---|
| PB | UB | PB | UB | PB | UB | PB | UB | |
| Before hydrolysis | 54.56 ± 2.16 eA | 151.10 ± 18.16 cB | 0.460 ± 0.012 dA | 1.910 ± 0.07 dB | 3.850 ± 0.82 dA | 8.880 ± 0.85 eB | 0.088 ± 0.002 bB | 0.079 ± 0.003 cA |
| Hydrolysate | 22.39 ± 1.17 dA | 27.10 ± 1.66 bB | 0.110 ± 0.009 cA | 0.200 ± 0.007 cB | 1.670 ± 0.66 cA | 1.760 ± 0.61 A | 0.110 ± 0.003 cA | 0.110 ± 0.001 dA |
| Peptide fraction | 1.07 ± 0.05 aA | 7.57 ± 0.76 aB | 0.045 ± 0.008 bA | 0.063 ± 0.001 bB | 0.054 ± 0.003 aA | 0.055 ± 0.004 aA | 0.083 ± 0.003 bB | 0.064 ± 0.002 bA |
| Peptide fraction | 7.6 ± 0.89 bA | 7.89 ± 1.09 aA | 0.017 ± 0.008 aA | 0.053 ±0.002 bB | 0.056 ± 0.002 aA | 0.072 ± 0.006 bB | 0.058 ± 0.013 aB | 0.046 ± 0.002 aA |
| Peptide fraction | 8.06 ± 0.77 cA | 7.79 ± 1.32 aA | 0.015 ± 0.004 aA | 0.027 ± 0.003 aB | 0.150 ± 0.001 bA | 0.170 ± 0.004 cB | 0.049 ± 0.007 aA | 0.076 ± 0.003 cB |
All values are the mean ± standard deviation for triplicate experiments. Different capital letters in the same row indicate significant differences for the same indicator (α = 0.05). Different lowercase letters in the same columns indicate significant differences for the same indicator (α = 0.05). The data were analysed with one-way analysis of variance (ANOVA), followed by Tukey’s multiple comparison procedure.
Inhibition of enzymes involved in metabolic syndrome pathogenesis (IC50).
| Sample | Lipase (mg mL−1) | α-Amylase (mg mL−1) | ACE (mg mL−1) | |||
|---|---|---|---|---|---|---|
| PB | UB | PB | UB | PB | UB | |
| Before hydrolysis | 0.23 ± 0.03 dA | 0.23 ± 0.04 dA | 2.37 ± 0.19 cA | 6.95 ± 0.99 bB | ND | ND |
| Hydrolysate | 0.05 ± 0.008 cA | 0.170 ± 0.01 cB | 1.54 ± 0.07 bA | 1.82 ± 0.05 aA | 8.57 ± 1.06 cA | 15.73 ± 1.61 dB |
| Peptide fraction <3.5 kDa | 0.008 ± 0.001 aA | 0.009 ± 0.0007 aA | 13.72 ± 1.11 dB | 9.22 ± 0.89 bA | 0.84 ± 0.06 bA | 1.11 ± 0.08 cB |
| Peptide fraction 3.5–7.0 kDa | 0.023 ± 0.02 bB | 0.009 ±0.0009 aA | 0.89 ± 0.01 aA | 27.31 ± 1.87 cB | 0.37 ± 0.009 aA | 0.95 ± 0.04 bB |
| Peptide fraction >7.0 kDa | 0.024 ± 0.03 bB | 0.013 ± 0.008 bA | ND | 10.26 ± 2.88 bA | 0.81 ± 0.006 bB | 0.59 ± 0.03 aA |
PB—packed string bean; UB—unpacked string bean; ND—not determined; All values are the mean ± standard deviation for triplicate experiments. Different capital letters in the same row indicate significant differences for the same indicator (α = 0.05). Different lowercase letters in the same columns indicate significant differences for the same indicator (α = 0.05). The data were analysed with one-way analysis of variance (ANOVA), followed by Tukey’s multiple comparison procedure.
Antimicrobial activity of peptide fractions.
| Sample | ||||
|---|---|---|---|---|
|
| ||||
| PB | Peptide fraction <3.5 kDa | 11.80 ± 1.30 a | 14.00 ± 1.00 a | nd |
| Peptide fraction 3.5–7.0 kDa | 13.00 ± 1.40 a | 13.50 ± 1.00 a | ||
| Peptide fraction >7.0 kDa | 12.50 ± 1.00 a | 13.5 ± 1.20 a | ||
| UB | Peptide fraction 3.5–7.0 kDa | 15.40 ± 1.20 a | 16.30 ± 1.50 a | |
| AMP | 13.50 ± 1.00 a | 13.00 ± 1.00 a | na | |
| NE | 23.50 ± 1.50 b | 26.20 ± 1.30 b | ||
|
| ||||
| PB | Peptide fraction <3.5 kDa | 0.50 | 0.50 | nd |
| Peptide fraction 3.5–7.0 kDa | 1.00 | 0.50 | ||
| Peptide fraction >7.0 kDa | 1.00 | 0.50 | ||
| UB | Peptide fraction 3.5–7.0 kDa | 0.50 | 0.25 | |
|
| ||||
| PB | Peptide fraction <3.5 kDa | 0.50 | 0.25 | nd |
| Peptide fraction 3.5–7.0 kDa | 0.50 | 0.25 | ||
| Peptide fraction >7.0 kDa | 0.50 | 0.25 | ||
| UB | Peptide fraction 3.5–7.0 kDa | 0.25 | 0.125 | |
* values are expressed as the mean ± SD; nd—not detected; na—not applicable; AMP—ampicillin (10 µg/disc); NE—neomycin (30 µg/disc); MIC—minimum inhibitory concentration; MBC—minimum bactericidal concentrations; PB—packed sreing bean; UB—unpacked string bean. Different letters in the same column indicate significant differences (α = 0.05).